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Atrial natriuretic peptide (ANP) is a peptide hormone that in
response to atrial stretch is secreted from atrial myocytes into
the circulation, where it stimulates vasodilatation and natriure-
sis. ANP is an important biomarker of heart failure where low
plasma concentrations exclude cardiac dysfunction. ANP is a
member of the natriuretic peptide (NP) family, which also
includes the B-type natriuretic peptide (BNP) and the C-type
natriuretic peptide. The proforms of these hormones undergo
processing tomature peptides, and for proBNP, this process has
previously been demonstrated to be regulated by O-glycosyla-
tion. It has been suggested that proANP alsomay undergo post-
translational modifications. Here, we conducted a targeted
O-glycoproteomics approach to characterize O-glycans on NPs
and demonstrate that all NP members can carry O-glycans. We
identified fourO-glycosites in proANP in the porcine heart, and
surprisingly, two of these were located on the mature bioactive
ANP itself. We found that one of these glycans is located within
a conserved sequencemotif of the receptor-binding region, sug-
gesting thatO-glycansmay serve a function beyond intracellular
processing and maturation. We also identified an O-glycoform
of proANP naturally occurring in human circulation. We dem-
onstrated that site-specific O-glycosylation shields bioactive
ANP from proteolytic degradation and modifies potency at its
cognate receptor in vitro. Furthermore, we showed that ANP
O-glycosylation attenuates acute renal and cardiovascular ANP
actions in vivo. The discovery of novel glycosylatedANPproteo-
forms reported here significantly improves our understanding
of cardiac endocrinology and provides important insight into
the etiology of heart failure.
The natriuretic peptide (NP)3 family comprises atrial natri-
uretic peptide (ANP), B-type natriuretic peptide (BNP), and
C-type natriuretic peptide (CNP), which are peptide hormones
involved in maintaining cardiorenal homeostasis. The cardiac
NPs, ANP and BNP, possess potent diuretic and natriuretic
effects as well as blood pressure-lowering properties that are
mediated through the natriuretic peptide receptor A (NPR-A),
whereas CNP is a potent anti-fibrotic and anti-remodeling fac-
tor acting through natriuretic peptide receptor B (NPR-B)
(1–5). All three NPs are synthesized as prohormones and sub-
sequently proteolytically activated by the proprotein converta-
ses corin and furin to form mature receptor-binding peptide
hormones. In circulation, NPs have short half-lives (i.e. min-
utes), presumably owing to processes like receptor-mediated
clearance, tissue-specific metabolism, and proteolytic degrada-
tion by neprilysin and insulin-degrading enzyme. In an attempt
to stabilize ANP, neprilysin inhibitors have recently been intro-
duced for chronic heart failure treatment (6–10), and notably
when neprilysin inhibition is combined with an angiotensin II
receptor antagonist, cardiovascular mortality is markedly re-
duced (6), emphasizing the therapeutic potential of NPs in car-
diovascular disease.
ProBNP is O-glycosylated, and O-glycans in close proximity
to the processing site of BNP have been suggested to co-regu-
late processing (11). ProBNP, BNP, and the processedN-termi-
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nal NT-proBNP are all found in circulation and serve as bio-
markers for the diagnosis of heart failure. It is well-established
that proBNP and NT-proBNP carry O-glycans of the GalNAc
type (11) and that the proportion of O-glycosylated proBNP
increases in chronic heart failure (12, 13).O-Glycans are known
to co-regulate proprotein processing (14), and studies demon-
strate thatO-glycans in close proximity to the furin-processing
site in proBNP affect activation of the peptide as well as anti-
body recognition (11, 14–20). It is thus believed that theO-gly-
cosylation of proBNP leads to an increase in the unprocessed
form in circulation and corresponding lower biological activity
(16, 21). However, comprehensive studies ofO-glycosylation of
the NPs aremissing.O-Glycosylation is themost abundant and
complex regulated type of protein glycosylation, and it is esti-
mated that80% of proteins trafficking the secretory pathway
are O-glycosylated (22). O-Glycosylation is initiated in the
Golgi by a family of up to 20 polypeptide GalNAc-transferase
(GalNAc-T) isoforms at serine and threonine (and possibly
tyrosine) residues. The multiple GalNAc-T isoforms are differ-
entially expressed in cells and tissues, which offers a high poten-
tial for regulation of specificO-glycosites. This also stresses the
need to evaluate different biological sources of proteins to
explore potentialO-glycosylation (23). It is currently not possi-
ble to reliably predictO-glycosites, and technical analytic chal-
lenges have long hampered identification ofO-glycosites at the
proteome level (24). However, recent advances in lectin enrich-
ment and glycoproteomics strategies have facilitated broad
screening and discovery of O-glycosites in cells and tissues
(25–28).
In this study, we performed a comprehensive glycoproteom-
ics analysis of human plasma and mammalian tissues with
known endogenous expression of NPs, using a sensitive lectin-
enriched glycoproteomics strategy. We discovered novel O-
glycans on all three NPs and surprisingly found O-glycans on
matureNPswith two glycosites inANPpositioned in the highly
conserved receptor-binding region and thus predicted to affect
bioactivity. We demonstrate that O-glycans on mature ANP
have amajor impact on stability and circulation time of ANP as
well as receptor activation by in vitro and in vivo studies in rats.
Results
ProANP, proBNP, and proCNP are O-glycoproteins
To explore O-glycans on NPs, we devised a fractionation
strategy in which we extracted water-soluble proteins (i.e. cyto-
solic and secretory granular proteins) from different tissues
(neonatal porcine atria, adult porcine ventricle, and human
prostate cancer tissue) known to express NPs at high levels.
We used a sequential enrichment strategy for O-glycopeptides
in combination with sensitive MS-based sequencing as de-
scribed previously (22, 24, 26). We predicted the most likely
O-glycoform in cardiac tissues to be sialylated core 1 structures
(ST (NeuAc2–3Gal1–3GalNAc1-O-Ser/Thr) and/or diST
(NeuAc2–3Gal1–3[NeuAc2–6] GalNAc1-O-Ser/Thr)).
We used pretreatment of samples with neuraminidase to
remove sialic acid residues to allow for efficient enrichment of
core 1 glycopeptides, using peanut agglutinin (PNA) lectin
weak affinity chromatography. Subsequent identification of
glycosites by tandem MS was done using higher-energy colli-
sion dissociation (HCD) and/or electron-transfer dissociation
(ETD) fragmentation. Identified glycopeptides were filtered to
include only NPs, and 16 NP O-glycopeptides were identified
by HCD and/or ETD fragmentation as summarized in Fig. 1A
(Fig. S1 and Table S1). We identified both core 1 and mono-
sialylated core 1 structures (Table S1), suggesting that the
neuraminidase pretreatment was partially incomplete.
We identified O-glycans on all three NP members, where
O-glycosylated proANP and proBNPwere identified in porcine
atrial cardiac tissues andO-glycosylated proCNPwas identified
only in human prostate cancer tissue. The NP protein se-
quences are conserved between humans and pigs, and all iden-
tified O-glycosites were within highly conserved sequence
motifs between the two species (Fig. S1). Fragmentation analy-
ses from both HCD and ETD MS/MS of tryptic O-glycopep-
tides covering proANP113–126, proBNP53–63, and proCNP3–28,
respectively, are shown in Fig. S2 (A–F). In proBNP, we con-
firmed the presence of twoO-glycans at Thr48 and Thr58 (posi-
tion numbers refer to proforms after signal peptide cleavage) in
the propeptide (Fig. 1B and Fig. S2 (C and D)), both of which
were previously identified in human proBNP (11, 29). In
proCNP, we found a singleO-glycan at Thr11 in the propeptide
(Fig. S2,E and F), whichwe previously identified in a SimpleCell
line (22). In proANP, we identified four novelO-glycosites with
two in the propeptide at Ser6/8 (ambiguously assigned site) and
at Ser80. Surprisingly, we identified two O-glycosites in the
matureANP at Ser117 and Ser123 (Fig. 1 (A andB), Table S1, and
Fig. S2 (A and B)), and interestingly, Ser117 is conserved in all
NPs. This represents the first O-glycosites in mature ANP.
Probing human ANPO-glycosites by in vitro enzyme
glycosylation
We next sought to test whether particular GalNAc-T iso-
forms would function with ANP using in vitro glycosylation
assays as described previously (30). Natriuretic peptides share a
characteristic disulfide bridge in the C-terminal region
(Cys105–Cys121 in proANP). We used both 20-mer partly over-
lapping synthetic peptides covering all potential Ser/Thr accep-
tor residues in proANP (peptides 1–9), mature ANP with the
disulfide bridge (peptide 10) (Fig. S3A), and a full-length
recombinant proANP1–126 protein (Fig. S3B). In human
proANP, the four glycosites identified in porcine proANP cor-
respond to Ser8 (Ser6 not conserved), Ser80, Ser117, and Ser123
residues, which are covered by peptides 1, 5/6, and 9/10 (Fig.
S3A). Most of these peptides did not serve as substrates for any
of the 12 tested recombinant GalNAc-T isoforms, although
peptide 5, but not 6, was, albeit poorly, utilized by GalNAc-T1
(Fig. S3A). Interestingly, the analysis indicated two other sub-
strate sites, Ser50 and Thr59/Ser63, in peptides 3 and 4 covering
the N-terminal propeptide, which served as substrates for sev-
eral GalNAc-T isoforms, including GalNAc-T1.
Next, we tested recombinant proANP1–126 as substrate for
the three most widely expressed GalNAc-T isoforms, T1, T2,
and T3, and monitored incorporation of GalNAc using VVA
lectin (31). In an overnight assay, we detected GalNAc incor-
poration by GalNAc-T1, but not by GalNAc-T2 and -T3 (Fig.
S3B). Incorporation of GalNAc by GalNAc-T1 resulted in
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slower migration of both pAb proANP1–16– and pAb
proANP99–126–immunoreactive bands corresponding to a
1–3-kDa increase in mass, suggesting that, at least in vitro,
both proANP and N-terminal proANP1–98 (NT-proANP)
are glycosylated by GalNAc-T1.
Identification of partially O-glycosylated proANP1–98 in
human plasma
In healthy individuals, proANP forms and ANP1–28 circulate
in low picomolar ranges, which is a likely reason why these
low-abundance proANP O-glycopeptides have not been
detected in human or animal plasma in our previous O-glyco-
proteomics studies (25, 32). To search for O-glycosylated
proANP in plasma, we therefore developed a state-of-the-art
Western blotting strategy for plasma samples with high endog-
enous concentrations of proANP in combination with ethanol
precipitation (Fig. 2A). We screened 20 plasma samples from
our clinical routine laboratory with increased proBNP concen-
trations and selected the three samples with the highest
proANP signal by Western blotting. We used a sensitive anti-
body directed to the first 16 amino acids of proANP, pAb
proANP1–16, and concluded that plasma proANP migrated
as a major band around 9–10 kDa with a variable slower-mi-
grating band at 14 kDa (Fig. 2A). The prominent faster-mi-
grating band at 9–10 kDa was concluded to correspond to NT-
proANP. We speculated that the slower-migrating band at 14
kDa could represent an O-glycoform of proANP and explored
this by treating the plasma sampleswith amixture of neuramin-
idase and O-glycanase to remove core 1 O-glycans. This
resulted in selective loss of the slower-migrating immunoreac-
tive band in all samples (Fig. 2A). We further treated a pool of
plasma samples with neuraminidase to remove only terminal
sialic acid residues, followed by immunoprecipitation and
detection using pAb proANP1–16, and this resulted in a mobil-
ity shift of the slowermigrating 14 kDa band by1–2 kDa (Fig.
2B). These results demonstrate that proANP in blood exists as
Figure 1. Summary of identified O-glycosites on natriuretic peptides. A, schematic representation of NPs with previously reported O-glycosites (yellow
squareswith diagonal line) and sites identified in this study (yellow squareswith bold, black frame). The NP pro-part is shown in blue, and themature bioactive
hormone is shown in red. Receptor binding involving the cyclic part of the bioactive hormones and their cognate receptors is shown on the right. Scissors
indicate corin or furin cleavage sites. A conserved serine in themature NPs is highlighted in boldface red type and with an asterisk andmarked with awhite box
on BNP and CNP. The six amino acids upstream of the proprotein convertase activation sites are shown with previously identified O-glycosites highlighted in
red. B, analysis of NP sequence conservation. The top panel shows conservation among all NPs in five species. The three bottom panels show the conservation
tracks for each NP as indicated. The conserved serine in the disulfide ring of ANP is highlighted in red and with an asterisk. Dark gray, complete conservation;
medium and light gray, less conservation; white, no conservation. All alignments were performed in ClustalW using the NP proprotein sequences of Homo
sapiens,Mus musculus, Xenopus laevis, O. mykiss, and A. japonica.
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multiple proteoforms with a minor fraction containing sialy-
lated core 1 O-glycans. Based on band intensities, we estimate
that the O-glycoform corresponds to10% of total circulating
proANP (Fig. 2A).
O-Glycosylation of ANP impacts proteolytic stability
ANP has a short half-life in circulation, ascribed to receptor-
mediated uptake and degradation by neprilysin and insulin-
degrading enzyme (33). Neprilysin inactivates ANP by initial
cleavage between Cys105 and Phe106, which opens the disulfide
ring, and insulin-degrading enzyme inactivates ANP by initial
cleavage between Ser123 and Phe124, truncating the C terminus
(34–36).O-Glycans in proximity of cleavage sites canmodulate
regulated proteolysis by, for example, proprotein convertases
and ADAM metalloproteinases (14, 37), so we hypothesized
that the O-glycans at Ser117 and Ser123 could impact degrada-
tion by neprilysin and insulin-degrading enzyme. To explore
this, we used an in vitro proteolysis time-course assay monitor-
ing cleavage of peptides and glycopeptides by semi-quantitative
MALDI-TOF MS analysis (38).
We found that neprilysin degraded ANP completely within
15 min, whereas ANP with the simplest GalNAc (Tn) mono-
saccharide O-glycan (Tn-ANPS117 and Tn-ANPS123) remained
at least partially intact after 60 and 15 min, respectively (Fig.
3A). A fraction of intact Tn-ANPS117,S123was still detected after
a 30-min incubation. In a similar time course with insulin-de-
grading enzyme, ANP was completely degraded within 15 min,
whereas Tn-ANPS117 andTn-ANPS123 remainedmainly as full-
length glycopeptides after 30–60 min of incubation (Fig. 3B).
Interestingly, Tn-ANPS117,S123 was degraded within 15 min.
O-Glycosylation of ANP affects receptor activation
On mature ANP, the two identified glycosites, Ser117 and
Ser123, are located in the receptor-binding region and predicted
to impact interaction with the atrial natriuretic peptide recep-
tor type A (NPR-A) (Fig. 1A). Ser117 is highly conserved in all
NPs, including Xenopus laevis, Oncorhynchus mykiss, and
Anguilla japonica (Fig. 1B), suggesting that this site may be
particularly important. To address the effect on receptor inter-
action, we produced a series of ANP glycopeptides correspond-
ing to those identified by a chemoenzymatic approach (39).
ANP glycopeptides with GalNAc residues at selected sites were
installed by Fmoc solid-phase synthesis, and the sialylated core
1 structures were generated by stepwise enzymatic glycosyla-
tion with purified recombinant Drosophila core 1 synthase
(dC1GalT1) and human 2,3-sialyltransferase (ST3Gal1) (Fig.
4, A and B).
To evaluate the influence of O-glycans on ANP activation of
the cognate receptors, we used HEK293 cells stably expressing
full-length coding constructs of human NPR-A or NPR-B (40).
Ligand efficacy and potency were evaluated by quantifying
accumulation of intracellular cGMP as a measure of receptor
activation. First, we tested a panel of ANP peptides and Gal-
NAc-glycopeptides in NPR-A (Fig. 4B) and NPR-B (Fig. S4),
and neither of these activated NPR-B. However, whereas non-
glycosylatedANP activatedNPR-Awithin the expected EC50 of
0.4–10 nM, the GalNAc-glycosylated ANP glycoforms with
O-glycans at either Ser117 or Ser123 reduced the EC50 65–140-
fold (Fig. 4,C andD), whereas the presence ofO-glycans at both
sites completely abolished receptor activation (Fig. S4C). To
examine the effects of the elongated natural core 1 O-glycan
structures, we tested core 1 (T), ST, and diST glycoforms, and
both T-ANPS117 and ST-ANPS117 diminished NPR-A activa-
tion additionally 3–5-fold compared with the Tn-glycoform,
whereas diST-ANPS117 did not reach full activation even at 10
M (Fig. 4C). T-ANPS123, ST-ANPS123, and diST-ANPS123
diminished NPR-A activation additionally 2–6-fold compared
with the Tn-glycoform (Fig. 4D). Elongated glycoforms of
ANPS123 tended to reach 80% efficacy, whereas ANPS123 glyco-
forms reached 120% efficacy comparedwithANP. Importantly,
treatment of Tn-ANPS117 with an exo--N-acetylgalac-
tosaminidase to remove GalNAc residues (41) restored the
EC50, showing that enzymatic treatment and repurification had
no effect on the functional state of ANP (Fig. S4D).
O-Glycosylation of ANP affects in vivo stability and activity
We further tested in vivo bioavailability and activity of ANP
glycoforms in rats. We measured mean arterial pressure
(MAP), renal actions, and peptide hormone changes in vivo in
normal rats with 60-min intravenous infusion of synthetic
ANP, ST-ANPS117, or ST-ANPS123, followed by 30-min post-
infusion clearance. Overall, ANP induced potent blood pres-
sure (BP)-lowering effect compared with ST-ANPS117 or ST-
ANPS123 during infusion (Fig. 5A). There is a trend that MAP
was sustained or further reduced by ST-ANPS117 and
ST-ANPS123 after infusion was completed compared with the
rebounding effect observed in the ANP group. Both urine out-
put (UV) and urinary sodium excretion (UNaV) were increased
by ANP infusion and not by glycosylated ANP (Fig. 5, B and C).
The enhanced cardiovascular and renal actions in the ANP
Figure2. Identificationof circulatingO-glycosylatedNT-proANP inhumanplasma.A,WesternblottingwithpAbproANP1–16 of plasma fromthreeplasma
samples with high endogenous proANP concentrations subjected to deglycosylation with a broad specificity of neuraminidase and O-glycanase. Band
intensities are shown above or below the respective bands. B, Western blotting with pAb proANP1–16 of plasma treated only with neuraminidase and immu-
noprecipitated (IP) with pAb proANP1–16. Arrows, 9–10 kDa bands; arrowswith one asterisk, 14 kDa bands; arrowwith two asterisks, 12–13 kDa band.
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group were accompanied by significant elevation of plasma
and urinary cGMP levels (Fig. S5, A and B). ST-ANPS123
tended to increase cGMP levels as well, and ST-ANPS117 had
only a minor effect on cGMP levels. Interestingly, infusion
with ST-ANPS123 or ST-ANPS117 presented markedly higher
ANP levels in both plasma and urine compared with the ANP
infusion group, indicating their exceptional stability in vivo
(Fig. S5, C and D).
Discussion
Recent advances in O-glycoproteomics have provided a new
perspective on the abundance of protein O-glycosylation and
how site-specific O-glycosylation regulated by individual
GalNAc-T isoforms serves distinct co-regulatory roles with
health impact (42). Here, we performed a targeted analysis of
NPs motivated partly by previous studies of BNP demonstrat-
ing a role ofO-glycosylation in processing (16) and partly by our
previous indication that antibodies to ANP were being blocked
by unexplainable modifications (43). Applying a sensitive tar-
geted glycoproteomics strategy to low-molecular weight pro-
teins and peptides led to the discovery of O-glycans on all NPs
and, of particular interest, the presence of O-glycans on the
mature NPs. We demonstrated with ANP that a conserved
O-glycosite in the receptor-binding region of NPs positively
affected circulatory half-life and negatively affected NPR-A
receptor activation in rats. The result adds another fundamen-
tal function to site-specific O-glycosylation in regulating pep-
tide hormones (42), and this may be more generally applicable
Figure 3. Proteolytic stability of ANP glycoforms. A and B, in vitro cleavage analysis of equal amounts of ANP and O-glycosylated ANP (Tn-ANPS117,
Tn-ANPS123, or Tn-ANPS117,S123) with either neprilysin (A) or insulin-degrading enzyme (B) in a time course up to 24 h. ANP peptide sequence with GalNAc
glycosylation and initial neprilysin and insulin-degrading enzymeproteolytic cleavage sites (vertical lines) and their expectedmasses after cleavage are shown
at the top of each panel. Samples were taken at the indicated time points, and the product development was monitored by MALDI-TOF MS. Intact ANP is
indicated by arrows, and products formed by proteolytic activity have either lower or slightly higher masses. Initial cleavage by neprilysin opens the disulfide
ring,which increases themass of intactANPwith 18Da,whereas initial cleavageby insulin-degradingenzyme leads to a loss of 466Da. After the initial cleavage
events, ANP is further degraded to products of lower masses. Assays were repeated 2–3 times with similar results, respectively. Mock treatment did not affect
the ANP signal over time (not shown).
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to short peptide hormones than currently appreciated given the
general difficulties with identifying O-glycans.
ANP binds to NPR-A through an asymmetric interaction
with the receptor homodimer, where the N-terminal part of
NPR-A binds to one receptor monomer and the C-terminal
part of ANP binds to the other receptor monomer (44). Thus,
the entire mature ANP peptide is important for the receptor
binding (45). Previous studies of ANP analogs have shown that
the highly conserved Ser117 residue in the C-terminal loop is
important for NPR-A binding, and substitution of this residue
with D-Ser diminishes binding (46). In agreement with this, we
found that the identified O-glycan at Ser117 in ANP decreased
its activation potency with NPR-A, and this effect was exacer-
bated by increasing the size of the attached O-glycan (Fig. 4).
Moreover, synthetic ANP glycoforms with O-glycans at both
Ser117 and Ser123 completely abolished activation of NPR-A,
although this glycoform with two O-glycans was not identified
in the studied biological samples.We also explored the interac-
tion of ANP glycoforms with the NPR-B receptor to evaluate
whether O-glycans could affect receptor subclass selectivity,
but all tested ANP glycoforms remained inactive with NPR-B
similarly to unmodified ANP. We did not test for binding to
NPR-C, and NPR-C has been suggested to have cardiovascular
activity that goes beyond its role as a clearance receptor where
Figure 4. Analysis of natriuretic peptide receptor type A activation with ANP glycoforms. A, illustration of the stepwise enzymatic synthesis of ANP
glycopeptides. Tn-ANP was synthesized using Fmoc solid-phase synthesis and used for further glycan elongation to produce T-ANP using Drosophila core 1
synthase (dC1GalT1), to ST-ANP using human -2,3-sialyltransferase 1 (ST3Gal1), and to diST using human GalNAc -2,6-sialyltransferase 1 (ST6GalNAc1). B,
table summary of peptides and glycopeptides used in receptor activation assays. All peptides were synthesized with a disulfide bridge. C, NPR-A activation
assay using ANP and glycosylated ANP variants on Ser117 and CNP as control.D, NPR-A activation assay using ANP and glycosylated ANP variants on Ser123 and
CNP control peptide. Receptor activation was measured by an increase in cGMP content in HEK293 cells stably expressing NPR-A stimulated by increasing
concentrations of peptides as indicated. The receptor activation data in C andD are directly comparable, since the experiment was performed simultaneously
on the same plates. The same ANP and CNP data are shown in both C and D for purposes of clarity and ease of comparison. Error bars, S.E.
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NPR-C activation leads to lowering of blood pressure (47–49).
Future studies on the cellular biology of ANP glycoforms
should include relevant primary cells or cell lines expressing
endogenous natriuretic peptide receptors.
Peptide hormones, including the NPs, are rapidly degraded
in circulation by neprilysin and insulin-degrading enzyme (36),
and inhibitors of neprilysin increase the effects of endogenous
NPs (50). The catalytic grooves of these enzymes provide for
their selective specificities of the small mature forms of NPs,
likely resulting from a molecular sieving function in domain 2,
restricting access by larger peptides to the active site (51).
O-Glycans are well-known to affect stability of proteins and in
many cases directly co-regulate limited proteolysis (14, 37, 52),
and the finding that mature ANP is stabilized by one or more
O-glycans in in vitroproteolysis assayswith neprilysin and insu-
lin-degrading enzyme is in agreement with this. We further
found that the proximity of theO-glycosites with the preferred
cleavage sites of neprilysin and insulin-degrading enzyme cor-
related with inhibition of proteolysis (Fig. 3), and the effect of
O-glycans on stability was confirmed in in vivo studies with
both plasma and urine. The position and size of the O-glycans
also affected receptor activation, and, perhaps surprisingly, the
presence of a single O-glycan at Ser117 or Ser123 reduced, but
did not abrogate, receptor activation (Fig. 4). O-Glycans are
uniquely suited to serve fine-tuned regulatory functions
because they are usually small and may be accommodated in
binding interactions and because they can be differentially reg-
ulated by one of themany isoenzymes orchestrating this type of
protein glycosylation, in contrast tomost other types of protein
glycosylation, including N-glycosylation (23). Further studies
are needed to address the biosynthetic and genetic regulation of
the identified O-glycans on NPs.
ANP and BNP are introduced in the clinical setting for infu-
sion therapy for decompensated heart failure (53–55). How-
ever, several studies have failed to demonstrate improved out-
come for patients, which, at least in part, appears to be because
of hemodynamic effects and the induction of hypotension (56,
57). Thus, current infusion strategies are based on low-dose
ANP administration over the course of several days (54). The
present results suggest that introduction ofO-glycans on these
NPs could improve therapeutic use by lowering and extending
receptor activation without the noted side effects. Our findings
may also, at least partly, explain the “endocrine paradox” in
congestive heart failure patients (58). These patients have
highly increased plasma NP concentrations concomitant with
edema. However, when administered recombinant BNP, they
elicit natriuresis, suggesting that endogenous NPs are blunted
in their bioactivity, and we hypothesize that this may be due to
alteredO-glycosylation of proBNP (15, 59). In support of this, it
appears that several key glycosyltransferases involved inO-gly-
cosylation initiation and elongation are up-regulated in heart
failure in the left ventricle of a rat model of hypertension-in-
duced cardiac hypertrophy (60).
In conclusion, our study suggests that all members of the NP
family are naturally O-glycosylated and that O-glycans on NPs
affect processing, receptor activation, and stability.We hypoth-
esize that O-glycoforms of NPs are produced to fine-tune tim-
ing and functions ofNPs and posit thatO-glycosylatedNPsmay
have potential for therapeutic use.
Materials andmethods
Sample preparation and nLC-MS/MS analysis
Atrial appendage tissue from 44 newborn piglets (61), one
normal porcine ventricle, and human prostate gland tissue
biopsies (pooled) (62) were collected. The local ethics commit-
tee approved the use of human tissue (KF 01287197), written
informed consent was obtained from all study participants, and
the study abides by the Declaration of Helsinki principles. Pro-
teins were extracted by crushing frozen tissue using a CryoPrep
tissue extractor (Covaris, Woburn, MA), boiled in water for 20
min, and homogenized with an Ultra-Turrax (IKA, Staufen,
Germany). After a 30-min centrifugation at 13,000  g, the
supernatants were collected and pooled, and protein concen-
tration was determined using a bicinchoninic acid assay
(Pierce). The prostate gland extract was then adjusted to 0.5 M
CH3COOH, precipitated by 20 °C acetone (67%), incubated
for 1 h at 20 °C, and centrifuged at 16,000  g for 30 min.
Subsequently, the supernatant was lyophilized and reconsti-
tuted in water.
An aliquot corresponding to 3 mg of protein for the heart
samples and 5 mg of protein for the prostate sample was
adjusted to 50 mM ammonium bicarbonate, reduced by 5 mM
DTT (30 min, 60 °C), and alkylated by adding 10 mM iodoacet-
Figure5.Acute in vivoactionsofO-glycosylatedANP.ANPorO-glycosylatedANPwith sialylated core1glycanoneither Ser117 or Ser123was infused into rats
for 60 min followed by a post-infusion clearance period of 30 min, andmean arterial pressure (MAP) (A), urinary output (UV) (B), and urinary sodium excretion
(UNaV) (C) were evaluated in the study. *, p 0.01 versus ST-ANPS117; #, p 0.05 versus ST-ANPS123; $, p 0.05 versus ST-ANPS117; ***, p 0.0001 versus all
groups; **, p 0.001 versus all groups (two-way ANOVA, Tukey’s post hoc tests). Error bars, S.D.
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amide (30 min, room temperature (RT)). The sample was then
digested with 50 g of trypsin (Roche Applied Science) (37 °C,
overnight), purified on C18 Sep-Pak (Waters), and desialylated
with 150 units of neuraminidase (P0720, New England Biolabs)
in 50mM sodium citrate (pH 6.0) (37 °C for 2 h). The digest was
Sep-Pak–purified, lyophilized, and resuspended in 2 ml of
PNA-binding buffer (10 mM HEPES (pH 7.4), 150 mM NaCl, 1
mM CaCl2, 0.1 mMMgCl2, MnCl2, and ZnCl2) and injected to a
pre-equilibrated 2.6-m-long PNA lectin-agarose column (Vec-
tor Laboratories). The flow was set to 100 l min1, and 1-ml
fractions were collected. The sample was eluted with 3  1
column volume of 0.5 M galactose, 1 M galactose, and 1 M galac-
tose, pH 3, respectively.
All samples were desalted on homemade StageTips (Empore
disk-C18, 3 M) (63, 64). The acidified samples were loaded on
the activated StageTips; washed with 0.1% formic acid; eluted
with 50% methanol, 0.1% formic acid; lyophilized; and finally
dissolved in 0.1% formic acid. Samples were analyzed on an
EASY-nLC 1000 LC system (Thermo Fisher Scientific) inter-
faced via nanoSpray Flex ion source to an LTQ-Orbitrap Velos
Promass spectrometer (Thermo Fisher Scientific). A precursor
MS1 scan (m/z 350–1,700) of intact peptides was acquired in
the Orbitrap at a nominal resolution setting of 30,000, followed
by Orbitrap HCD-MS2 and ETD-MS2 (m/z of 100–2,000) of
the five most abundant precursor ions in the MS1 spectrum; a
minimumMS1 signal threshold of 50,000 was used for trigger-
ing data-dependent fragmentation events; and MS2 spectra
were acquired at a resolution of 7,500 for HCDMS2 and 15,000
for ETD MS2. Activation times were 30 and 200 ms for HCD
and ETD fragmentation, respectively; isolation width was 4
mass units, and usually 1microscanwas collected for each spec-
trum. Automatic gain control targets were 1,000,000 ions for
Orbitrap MS1 and 100,000 for MS2 scans, and the automatic
gain control for the fluoranthene ion used for ETDwas 300,000.
Supplemental activation (20%) of the charge-reduced species
was used in the ETD analysis to improve fragmentation.
Dynamic exclusion for 60 s was used to prevent repeated anal-
ysis of the same components. Polysiloxane ions at m/z
445.12003 were used as a lock mass in all runs.
Data analysis
Data processing was performed using Proteome Discoverer
version 1.4 software (Thermo Fisher Scientific), using Sequest
HT node as described previously with small changes (22). All
spectra were initially searched with the full cleavage specificity,
filtered according to the confidence level (medium, low, and
unassigned), and further searched with the semi-specific enzy-
matic cleavage. In all cases, the precursor mass tolerance was
set to 6 ppm, and fragment ion mass tolerance was set to 50
milli-mass units. Carbamidomethylation on cysteine residues
was used as a fixed modification. Methionine oxidation and
HexNAc and HexHexNAc, HexNAcNeuAc, and HexHexNAc-
NeuAc attachment to serine, threonine, and tyrosine were used
as variable modifications for ETD MS2. All HCD MS2 scans
were preprocessed as described (22) and searched under the
same conditions mentioned above using only methionine oxi-
dation as a variable modification. All spectra were searched
against a concatenated forward/reverse Sus scrofa (pig)-specific
database (UniProt, February 2014, containing 33,652 canonical
entries) or human-specific database (UniProt, January 2013,
containing 20,232 canonical entries) using a target false discov-
ery rate of 1%. FDR was calculated using target decoy PSM
validator node, a part of the Proteome Discoverer workflow.
The resulting list was filtered to include only NPs with glyco-
sylation as a modification. The full data set will be published
elsewhere and made available at the GlyocDomainViewer
(https://glycodomain.glycomics.ku.dk)4 (65).
Peptide synthesis, in vitro glycosylation, and glycan
elongation
Synthetic ANP and CNP peptides (Phoenix Pharmaceuti-
cals), synthetic 20-mer ANP peptides (NeoBioLab), and
ANP-Tn peptides (Synpeptide) were confirmed to elicit correct
mass byMALDI-TOF analysis, and selected peptides were ana-
lyzed for purity by reverse-phase HPLC. Recombinant proANP
(Immundiagnostik) was produced in Escherichia coli.
In vitro glycosylation of peptideswas performed in 25l of 25
mM cacodylic acid sodium, pH 7.4, 10mMMnCl2, 0.25% Triton
X-100, 4mMUDP-GalNAc (Sigma), 10g of acceptor peptides,
and 0.2 g of purified recombinant glycosyltranferase enzyme.
All reactions were incubated at 37 °C, and product develop-
ment was evaluated by a Bruker Autoflex MALDI-TOF instru-
ment with accompanying Compass version 1.4 FlexSeries soft-
ware. Glycosylation of recombinant proANP was performed as
above using 1 g of acceptor protein and 0.6 g of purified
recombinant glycosyltransferase with complete EDTA-free
protease inhibitor mixture (Roche Applied Science).
ANP-Tn peptides were elongated to T by enzymatic treat-
ment with recombinant purified Drosophila core 1 synthase in
100 mM MES, 0.1% Triton X-100, 20 mM MnCl2, and 0.5 mM
UDP-Gal at 37 °C (39). After purification by reverse-phase
HPLC (C18), the glycan was further elongated to ST by enzy-
matic treatment with recombinant purified 2,3-sialyltransfer-
ase in 25 mM Tris (pH 6.5) and 2 mM CMP-Neu5Ac at 37 °C
and purified by reverse-phase HPLC (C18). GalNAc from Tn-
ANP117 was removed by enzymatic treatment by exo--N-
acetylgalactosaminidase (41) in 100 mM Tris (pH 7.4) and puri-
fied by reverse-phase HPLC (C18). Chemoenzymatically
elongated glycopeptides and Azyme-treated Tn-ANPS119 were
quantified by reverse-phase HPLC (C18) using ANP (95%,
Phoenix Pharmaceuticals) as standard peptide.
Deglycosylation of plasma andWestern blotting
For the human samples, the department has a general
approval for using humanmaterial for analytical purposeswith-
out specific applications to the local ethics committee. All sam-
ples were anonymized prior to analyses without any possible
traceability to the patient. Plasma from patients with elevated
endogenous proBNP (100 pM) was diluted 1:1 with 50 mM
phosphate buffer, pH 6, and incubated with 10 milliunits of
broad neuraminidase (Merck Millipore, catalogue no. 480716)
and 2milliunits ofO-glycanase (MerckMillipore, catalogue no.
324716) for 16 h at 37 °C and subsequently precipitated by eth-
4 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
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anol (64%), vortexed, and centrifuged at 4,000 g for 20min at
4 °C. The pellet was discarded, and the supernatant was dried in
a SpeedVac and resuspended in water. For specific removal of
sialic acids, the sample was treated with 100 units of 2–3,6,8-
neuraminidase (NewEngland Biolabs) for 1 h at 37 °C on 330l
of supernatant in a total volume of 1 ml in 50 mM sodium ace-
tate, pH 5. For immunoprecipitation, samples were precipi-
tated with rabbit pAb NT-proANP1–16 (66) using Dynabeads
protein A (Thermo Fisher Scientific) according to the manufa-
cturer’s instructions.
All sampleswere runon16%/10%/6%Tris-Tricine gels at 125
V for 90 min and transferred to nitrocellulose membranes, and
nonspecific binding was blocked using 5% skim milk in TBST.
The blocked membranes were incubated with primary anti-
body pAb NT-proANP1–16 or pAb proANP99–126 diluted
1:1,000 overnight at 4 °C followed by secondary antibody goat
anti-rabbit IgG coupled to horseradish peroxidase (Cell Sig-
naling) diluted 1:2,000 for 1 h at RT. For lectin blots, 1%
polyvinylpyrrolidone was used as blocking reagent, and lec-
tin used was VVA-biotin (Vector Laboratories) diluted
1:2,000 overnight at 4 °C followed by secondary antibody
streptavidin coupled to horseradish peroxidase (Dako, Agi-
lent) diluted 1:4,000 for 1 h at RT. For development, Super-
Signal West Pico Chemiluminescent Substrate (Thermo Sci-
entific) was used on an Odyssey Fc Imaging System (LI-COR
Biosciences). Band intensities were calculated using Image
Studio version 2.0.38 (LI-COR Biosciences) and are shown as
signal/area  105.
ANP receptor cGMP activation assay
The cGMP content in HEK293 cells stimulated with peptide
was measured using the cGMP kit (Cisbio) according to the
manufacturer’s instructions. Briefly, HEK293 cells stably
expressing either human NPR-A or human NPR-B (40) were
resuspended in Dulbecco’s modified Eagle’s medium buffer
supplemented with 25mMHEPES, pH 7.4, 0.1% BSA, and 1mM
3-isobutyl-1-methylxanthine (Sigma) to achieve a cell density
of 0.4 million cells/ml. Stimulated cells (2,000 cells/well) were
incubated at 37 °C for 30 min before the cells were lysed, anti-
cGMP cryptate conjugate and cGMP-d2 conjugate were added,
and the plate was incubated for 1 h at room temperature. The
plate was read on an Enspire Multilabel Reader (PerkinElmer
Life Sciences) with excitation at 340 nm and measurements of
emission at 615 and 665 nm. The FRET ratios (665/615 nm)
were converted into cGMPconcentrations by interpolating val-
ues from a cGMP standard curve.
Proteolytic degradation assay
In vitro cleavage activity was assayed by adding 1 ng of nepri-
lysin (R&D Systems) or 50 ng of insulin-degrading enzyme
(R&D Systems) to 325 pmol of peptide or glycopeptide sub-
strate in a total volume of 10l. Reactionswere performed in 50
mMTris, 0.05% Brij-35, pH 9 (neprilysin), or 50mMTris, 20mM
NaCl, pH 7.5 (insulin-degrading enzyme), and incubated at
37 °C. Product development was monitored after 15 min, 30
min, 60 min, and 24 h by MALDI-TOF analysis.
In vivo evaluation of glycosylated ANP
We investigated the BP actions of equimolar doses of
(600 pmol/kg/min) ANP, ST-ANPS117, or ST-ANPS123 (n 
4/group) in normal male Sprague–Dawley rats (250–350 g;
Charles River Laboratories, Wilmington, MA). Studies were
performed in accordance with the Animal Welfare Act and
with approval of theMayoClinic Institutional Animal Care and
Use Committee.
Anesthesia in rats was induced with 133 mg/kg intraperito-
neal inactin (Sigma), and rats weremaintained on a heating pad
for 1 h until complete anesthesia was achieved. With oxygen
flow, the rats were then subjected to catherizations and blood
and urine collections (2). A polyethylene (PE)-50 tube catheter
was placed into the jugular vein for intravenous (i.v.) saline and
peptide infusion. The carotid artery was cannulated with a
PE-50 tube catheter for BP measurement (Sonometrics, Lon-
don, Canada). After completion of the above procedural setup,
a 45-min equilibration period was performed, which included
continuous i.v. saline infusion. After the 45-min equilibra-
tion period, baseline (0min) BP was recorded. The inulin and
saline infusion was replaced by continuous i.v. infusion of
either ANP, ST-ANPS117, or ST-ANPS123 for 60 min. The
infusion rate was weight-adjusted and equals the weight 
0.7/6,000 ml/min. A post-infusion clearance (time 60–90
min) was performed for 30 min. At the end of the study,
blood was collected to determine plasma ANP and cGMP
levels by radioimmunoassay and ELISA. Glycosylation on
Ser-117 of ANP underestimates the actual ST-ANPS117 con-
centration (data not shown). Urine was collected at the end
of the infusion and post-infusion clearances (time  60 and
90 min). Urinary sodium was measured with pHOx Ultra
(Nova Biomedical, Waltham, MA). UV and UNaV were cal-
culated as urine volume or sodium clearance per min. Uri-
nary cGMP and ANP excretion rate were calculated based on
raw concentrations obtained in the urine and UV.
Statistical analysis
In vitro receptor activation data are represented as mean 	
S.E. In vivo data are represented as mean 	 S.D. One-way
ANOVA was used for comparison of more than two groups,
followed by Tukey’s post hoc tests, and two-way ANOVA was
used when multiple time points were involved. Unpaired t test
was used for comparison of two groups. Statistical significance
is defined as p  0.05 (two-tailed). Data were analyzed with
GraphPad Prism version 8 software.
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